Immunic

IMUX

Market cap $123M

Immunic Inc (NASDAQ:IMUX) earlier this week outlined how a newly secured up to $400 million private placement is set to support completion of late-stage trials and prepare the company for a potential commercial launch of vidofludimus calcium in multiple sclerosis. Speaking to Proactive, CEO Dr Daniel Vitt described the financing as “a transformative transaction for the company,” noting that $200 million has already been received, with the remainder available in a second tranche.

Immunic Inc (NASDAQ:IMUX) said it is entering a pivotal period for its multiple sclerosis program after securing up to $400 million in new financing and advancing its lead drug into late-stage development, with key data expected by the end of 2026. The biotechnology company's oral candidate, vidofludimus calcium (IMU-838), is currently being evaluated in the twin phase 3 ENSURE-1 and ENSURE-2 trials in relapsing multiple sclerosis (RMS).

– Top-Line Data from Phase 3 ENSURE Trials of Vidofludimus Calcium in Relapsing Multiple Sclerosis Expected by Year-End 2026 – – Raised Proceeds of $200 Million in a Private Placement, with Potential for up to an Additional $200 Million – – Net Proceeds Expected to Fund Completion of Phase 3 ENSURE Trials in Relapsing Multiple Sclerosis, Initiation of Phase 3 Trial in Primary Progressive Multiple Sclerosis and Begin of Transition into a Commercial Organization – NEW YORK, Feb. 26, 2026  /PRNewswire/ --  Immunic, Inc.  (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic and gastrointestinal diseases, today announced financial results for the year ended December 31, 2025, and provided a corporate update. "The phase 3 ENSURE-1 and ENSURE-2 trials of our lead asset, orally available nuclear receptor-related 1 (Nurr1) activator, vidofludimus calcium (IMU-838) in relapsing multiple sclerosis (RMS) continue to progress, with top-line data expected to be available by the end of 2026," stated Daniel Vitt, Ph.D.

Immunic Inc (NASDAQ:IMUX) said on Tuesday it has closed a previously disclosed private placement financing, raising $200 million upfront with the potential to secure up to an additional $200 million. The New York-based biotechnology company issued just over 229 million pre-funded warrants at a price of $0.873 each, generating gross upfront proceeds of $200 million.

– Upfront Proceeds of USD 200 Million, with Potential for up to USD 200 Million in Additional Proceeds – – Expected to Fund Completion of Phase 3 ENSURE Trials in Relapsing Multiple Sclerosis, Initiation of Phase 3 Trial in Primary Progressive Multiple Sclerosis, and Begin of Transition Into a Commercial Organization – NEW YORK, Feb. 17, 2026 /PRNewswire/ --  Immunic, Inc.  (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic and gastrointestinal diseases, today announced the closing of its previously disclosed private placement financing. The financing was led by BVF Partners L.P.

Immunic Inc (NASDAQ:IMUX)'s chief medical officer Dr Andreas Muehler talked with Proactive about new data presented at the ACTRIMS Forum in San Diego, highlighting findings from the company's phase 2 CALIPER trial in progressive multiple sclerosis (MS). Proactive: Hello, you're watching Proactive.

Immunic Inc (NASDAQ: IMUX) is surging Friday after the late‑stage biotech announced a private placement of up to $400 million.

Immunic Inc (NASDAQ:IMUX) announced that it has priced an oversubscribed private placement expected to generate up to $400 million in gross proceeds as the biotechnology company works to transition toward commercialization of its multiple sclerosis pipeline. The financing includes $200 million in upfront proceeds through the issuance of 229,076,000 pre-funded warrants priced at $0.873 each, with the potential for an additional $200 million from accompanying warrants if exercised.

– Upfront Proceeds of USD 200 Million, with Potential for up to USD 200 Million in Additional Proceeds – – Expected to Fund Completion of Phase 3 ENSURE Trials in Relapsing Multiple Sclerosis, Initiation of Phase 3 Trial in Primary Progressive Multiple Sclerosis, and Transition into a Commercial Organization – – Simona Skerjanec, Former SVP, Global Head of Neuroscience and Rare Diseases at Roche, Elevated to Interim Chairperson of the Board of Directors – – Thor Nagel, Principal at BVF Partners L.P., Joins Board of Directors – – Simona Skerjanec and Dr. Daniel Vitt to Lead Search for CEO with Commercial Background – NEW YORK, Feb. 13, 2026 /PRNewswire/ -- Immunic, Inc.  (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic and gastrointestinal diseases, today announced the pricing of a private placement with gross proceeds of up to USD 400 million priced at the market under Nasdaq rules.

Immunic Inc (NASDAQ:IMUX) said it will present additional analyses from its Phase 2 CALLIPER trial of vidofludimus calcium (IMU-838) in patients with progressive multiple sclerosis (PMS) at the ACTRIMS Forum 2026, which is being held from February 5 to 7 in San Diego. Vidofludimus calcium is described by Immunic as a nuclear receptor-related 1 (Nurr1) activator and selective dihydroorotate dehydrogenase (DHODH) inhibitor.